Inventor · disambiguated record
Daniel J. Sexton
Also filed as: SEXTON DANIEL J
43 granted patents·19 pending applications·333 citations·filing 2003–2024
98Inventor score
Top patents by PatentIndex Score
62 records- 0197US10370453B2Plasma kallikrein binding proteinsDYAX CORP·Filed 2015·Granted Aug 6, 2019·25 cites·9 claims
- 0296US11505620B2Methods of detecting plasma kallikreinTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Nov 22, 2022·6 cites·20 claims
- 0396US8822653B2Plasma kallikrein binding proteinsSEXTON DANIEL J·Filed 2011·Granted Sep 2, 2014·27 cites·32 claims
- 0495US12084515B2Compositions and methods for treatment of diabetic macular edemaTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Sep 10, 2024·4 cites·10 claims
- 0595US11084884B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2015·Granted Aug 10, 2021·23 cites·17 claims
- 0695US11046785B2Compositions and methods for treatment of diabetic macular edemaDYAX CORP·Filed 2019·Granted Jun 29, 2021·11 cites·7 claims
- 0795US10648990B2Diagnosis and treatment of autoimmune diseasesDYAX CORP·Filed 2018·Granted May 12, 2020·7 cites·10 claims
- 0895US9266964B2Method of treating hereditary angioedema using plasma kallikrein binding antibodiesDYAX CORP·Filed 2014·Granted Feb 23, 2016·24 cites·6 claims
- 0995US8816055B2Plasma kallikrein binding proteinsSEXTON DANIEL J·Filed 2012·Granted Aug 26, 2014·29 cites·7 claims
- 1094US12061206B2Diagnosis and treatment of autoimmune diseasesTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 13, 2024·3 cites·13 claims
- 1194US7329737B2Antibodies that bind hK-1DYAX CORP·Filed 2005·Granted Feb 12, 2008·54 cites·17 claims
- 1293US11340237B2Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2017·Granted May 24, 2022·7 cites·26 claims
- 1393US10336832B2Methods of inhibiting plasma kallikrein in edema patientDYAX CORP·Filed 2014·Granted Jul 2, 2019·13 cites·7 claims
- 1492US10914747B2Immunoassay to detect cleaved high molecular weight kininogenDYAX CORP·Filed 2016·Granted Feb 9, 2021·6 cites·50 claims
- 1592US10428158B2Compositions and methods for treatment of diabetic macular edemaDYAX CORP·Filed 2015·Granted Oct 1, 2019·14 cites·9 claims
- 1691US9862768B2Methods of producing antibodies to neonatal Fc receptor (FcRn)DYAX CORP·Filed 2016·Granted Jan 9, 2018·7 cites·12 claims
- 1790US11372002B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Jun 28, 2022·9 cites·15 claims
- 1889US11739152B2Antibodies which bind Fc receptors (FcRn)TAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Aug 29, 2023·1 cites·16 claims
- 1989US11458477B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Oct 4, 2022·1 cites·20 claims
- 2089US11401346B2Nucleic acids encoding plasma kallikrein binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2019·Granted Aug 2, 2022·5 cites·21 claims
- 2189US11014988B2Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodiesDYAX CORP·Filed 2019·Granted May 25, 2021·2 cites·19 claims
- 2288US10479834B2Fc receptor antibodies and methods of use thereofDYAX CORP·Filed 2017·Granted Nov 19, 2019·4 cites·16 claims
- 2388US9359438B2Human neonatal Fc receptor antibodies and methods of use thereofSEXTON DANIEL J·Filed 2012·Granted Jun 7, 2016·9 cites·17 claims
- 2488US8642010B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapySATO AARON K·Filed 2009·Granted Feb 4, 2014·9 cites·42 claims
- 2587US12454575B2Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodiesTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Oct 28, 2025·0 cites·22 claims
- 2687US11156612B2Methods of determining levels of cleaved and/or intact kininogenTAKEDA PHARMACEUTICALS CO·Filed 2014·Granted Oct 26, 2021·6 cites·15 claims
- 2787US10101344B2Diagnosis and treatment of autoimmune diseasesDYAX CORP·Filed 2014·Granted Oct 16, 2018·8 cites·18 claims
- 2887US7993646B2HK1-binding proteinsDYAX CORP·Filed 2007·Granted Aug 9, 2011·11 cites·27 claims
- 2986US10870115B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationDYAX CORP·Filed 2016·Granted Dec 22, 2020·2 cites·20 claims
- 3085US12460016B2Plasma kallikrein binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Nov 4, 2025·0 cites·8 claims
- 3184US2025199014A1Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 3283US12384854B2Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2020·Granted Aug 12, 2025·1 cites·15 claims
- 3383US11826758B2Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activationTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Nov 28, 2023·0 cites·20 claims
- 3482US11668718B2Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWKTAKEDA PHARMACEUTICALS CO·Filed 2016·Granted Jun 6, 2023·2 cites·14 claims
- 3581US2025172567A1Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwkTAKEDA PHARMACEUTICALS CO·Filed 2024·Application pending·0 cites
- 3680US12135329B2Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWKTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Nov 5, 2024·0 cites·17 claims
- 3780US10913802B2Monoclonal antibody inhibitor of factor XIIADYAX CORP·Filed 2016·Granted Feb 9, 2021·3 cites·15 claims
- 3880US2023112931A1Plasma kallikrein binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2022·Application pending·0 cites
- 3977US12188948B2Metabolite biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2022·Granted Jan 7, 2025·0 cites·18 claims
- 4077US2024142468A1Protein biomarkers for diseases associated with the contact activation systemTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 4175US12442824B2Assays for determining plasma kallikrein system biomarkersTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Oct 14, 2025·0 cites·9 claims
- 4275US2024271211A1Rna biomarkers for hereditary angioedemaTAKEDA PHARMACEUTICALS CO·Filed 2023·Application pending·0 cites
- 4371US12493047B2Cleaved high molecule weight kininogen (HMWK) antibodies and methods of usingTAKEDA PHARMACEUTICALS CO·Filed 2021·Granted Dec 9, 2025·0 cites·4 claims
- 4470US9629934B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyDYAX CORP·Filed 2013·Granted Apr 25, 2017·0 cites·15 claims
- 4569US9446155B2KDR and VEGF/KDR binding peptides and their use in diagnosis and therapyDYAX CORP·Filed 2013·Granted Sep 20, 2016·0 cites·20 claims
- 4667US2018002447A1Plasma kallikrein binding proteinsDYAX CORP·Filed 2017·Application pending·0 cites
- 4767US2018037665A1Plasma kallikrein binding proteinsDYAX CORP·Filed 2017·Application pending·0 cites
- 4867US2018002449A1Plasma kallikrein binding proteinsDYAX CORP·Filed 2017·Application pending·0 cites
- 4967US2018002448A1Plasma kallikrein binding proteinsDYAX CORP·Filed 2017·Application pending·0 cites
- 5067US2018037666A1Plasma kallikrein binding proteinsDYAX CORP·Filed 2017·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel J. Sexton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →